Background: The prevalence of hyperuricemia is increasing globally. The health check‐up population is a group of people dedicated to disease prevention in public health. This study aims to estimate the current prevalence of hyperuricemia among the health check‐up population in economically developed areas of China using a healthcare database.Method: Healthcare data from 48,988 subjects in 12 provinces of China who had an annual health check‐up in 2021 were used. Hyperuricemia was defined as a serum urate level > 420 mmol/L and/or a history of physician‐diagnosed gout. An alternative definition of serum urate level > 420 mmol/L in men and > 360 mmol/L in women was used. The stratified prevalence of hyperuricemia by sex, age, region, and comorbidity group was reported. The association between hyperuricemia and sex, age, region, and comorbidities was analyzed in the multivariate logistic regression model.Results: In 2021, the sex‐ and age‐adjusted prevalence of hyperuricemia was 13.6% in the total population (24.3% in men and 2.6% in women) based on the definition of serum urate level > 420 mmol/L. Regional prevalence varied considerably across the country, with the highest prevalence found in Fujian and the lowest in Liaoning Province (21.6% vs. 7.3%). Male sex, aging, hypertension, obesity, abdominal obesity, hypertriglyceridemia, and hypercholesterolemia were likely to be associated with hyperuricemia.Conclusions: This is the largest study using a healthcare database to indicate the prevalence of hyperuricemia in a health check‐up population in an economically developed area of China. The current prevalence among the Chinese health check‐up population was substantial, with a higher prevalence in males and in the eastern region. Hyperuricemia and its comorbidities warrant greater attention in the developed areas of China.

Introduction: Children with special healthcare needs (CSHCN) often experience vaccination delays or missed vaccines in China. The coverage rate of the age-appropriate National Immunisation Programme vaccine was suboptimal. This study aimed to explore attitudes, behaviours, and suggestions regarding the improvement of routine vaccination services for CSHCN among healthcare providers. Methods: This study conducted local, cross-sectional interviews involving vaccination services for CSHCN. A purposive sampling strategy was used to recruit interviewees including primary care providers, paediatricians and immunisation programme administrators. The interview guide explored attitudes towards and suggestions for establishing immunisation advisory clinics and referral networks, updating immunisation guidance documents and vaccine package inserts and strengthening the education of vaccination providers. Results: 21 representative healthcare providers were interviewed. 10 measures were proposed to promote routine immunisation for children with special needs: (1) using immunisation advisory clinics to provide vaccination services for CSHCN; (2) establishing a referral network and specifying which cases necessitate referral to advisory clinics; (3) using an interconnected information system to identify, document and follow-up the CSHCN; (4) supporting high-quality clinical research to update immunisation protocols; (5) providing clear and definite immunisation recommendations to parents of eligible CSHCN; (6) seeking immunisation advice from specialised professionals to enhance primary care capability; (7) creating quality improvement programmes; (8) considering immunisation status a mandatory assessment during specialist visits; (9) supporting off-label use of vaccines legally and (10) encouraging pharmaceutical companies to update vaccine package inserts. Conclusion: Vaccine uptake among CSHCN in China is suboptimal, highlighting the need for a referral network and a standard immunisation protocol. The National Immunisation Programme should develop clear recommendations and an education programme for regional Centers for Disease Control and Prevention to train local providers. A quality assurance and improvement programme, along with regular feedback, is essential to ensure CSHCN receive necessary vaccinations and protection against infectious diseases.

Vaccine hesitancy is a common issue for children with immune thrombocytopenia (ITP) in China. The objective of this paper is to assess the immunization statuses of children with ITP, analyze the possible relationship between immunization and thrombocytopenia, and evaluate the safety of immunization after ITP remission. We included 186 children with an ITP history and followed up with them for two years after receiving re-immunization recommendations. The participants had an overall age-appropriate vaccine coverage of 57.9%. Vaccine-associated thrombocytopenia occurred in 99 (53.2%, 95% CI = 46.06–60.26) children ranging from 0 to 34 days following immunization, with 14 vaccines involved. One hundred and fifty-four (82.3%, 95% CI = 76.72–87.54) children were advised to restart immunization, whereas 32 (17.2%, 95% CI = 12.46–23.28) were advised to postpone partial or full vaccination. Following the follow-up, 150 (80.6%, 95% CI = 74.37–85.68) children completed the catch-up immunization, whereas 27 (14.5%, 95% CI = 10.17–20.30) partially completed it. Four patients with thrombocytopenia relapsed following the re-immunization. Incomplete catch-up immunization was related to the factors of chronic thrombocytopenia, vaccine-associated thrombocytopenia, and the relapse of ITP following re-immunization. ITP may occur after immunization with vaccines other than measles-containing vaccines. Re-immunization in children with ITP generally does not result in a relapse, regardless of whether the previous thrombocytopenia was vaccine-associated.

Viewpoints of investigator on CONSORT 2025 statement-updated guideline for reporting randomized trials

1. Precision medicine therapies such as complement inhibitors have transformed outcomes for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome (aHUS), IgA nephropathy, myasthen...